App-Quantinova.ai

ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) DEFINED REMISSION IS AS STRINGENT AS ACR/EULAR BOOLEAN-DEFINED REMISSION IN A CLINICAL TRIAL OF PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT

Y. Yazici - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Abatacept

THE COAGULATION STATE IN FEMALE PATIENTS WITH RHEUMATOID ARTHRITIS AND EARLY ATHEROSCLEROSIS

N.A. Bashlakova - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Vasodilation dysfunction

ILS-969

A LINK OF AUTOIMMUNE INFLAMMATION AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

N.A. Bashlakova - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

ILS-969

BASELINE MRI/CRP AS PREDICTORS OF RESPONSE TO ETANERCEPT IN THE MANAGEMENT OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

M.A. Brown - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

Etanercept

CHANGES IN THE METABOLISM OF HYALURONAN ARE ASSOCIATED WITH INFLAMMATORY CYTOKINES IN PATIENTS WITH ANKYLOSING SPONDYLITIS

U. Hellman - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

Hyaluronic acid

SERUM LEVEL OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR IS ELEVATED IN ANKYLOSING SPONDYLITIS AND OSTEOCALCIN MAY BE RELATED WTH OSTEOPROLIFERATION

D. Solmaz - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

Interleukin

SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE PATIENTS AND PATIENTS PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (MEASURE 2) IN ACTIVE ANKYLOSING SPONDYLITIS

J. Sieper - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

secukinumab

EARLY CLINICAL RESPONSE IS A BETTER PREDICTOR OF LONG-TERM REMISSION THAN BASELINE DISEASE CHARACTERISTICS FOLLOWING ADALIMUMAB TREATMENT IN PERIPHERAL SPONDYLOARTHRITIS

F. Van Den Bosch - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Peripheral spondyloarthritis

Adalimumab

ANXIETY-DEPRESSIVE SPECTRUM AND COGNITIVE DISORDERS IN BEHCE-S DISEASE PATIENTS

D. Ishchenko - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

Fibrinogen (IV)

EFFECT OF EXERCISE AND DIETARY WEIGHT LOSS ON SYMPTOMS AND SYSTEMIC INFLAMMATION IN OBESE ADULTS WITH PSORIATIC ARTHRITIS: RANDOMIZED CONTROLLED TRIAL

A. Abou-Raya - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Systemic inflammation

ILS-969

EFFECTS OF SARILUMAB PLUS MTX ON CLINICAL, RADIOGRAPHIC, AND FUNCTIONAL ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY

M. Genovese - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

ANTIPHOSPHOLIPID SYNDROME AND MARCERS OF INFLAMATION

N. Seredavkina - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Antiphospholipid syndrome

Interleukin

ASSESSMENT OF LEFT VENTRICULAR DYSSYNCHRONY IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER

N. Ustun - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Familial Mediterranean fever

Deutetrabenazine

SURFACTANT PROTEIN-D, A COMPONENT OF THE INNATE IMMUNE DEFENCE, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS

H. L. Munk - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Axial spondyloarthritis

N/A

INTERLEUKIN-1 DUAL VARIABLEDOMAIN IMMUNOGLOBULIN REDUCES MULTIPLE IMFLAMMATORY MARKERS IN KNEE OSTEOARTHRITIS PATIENTS

S. X. Wang - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Systemic inflammation

Interleukin

LOW GRADE SYSTEMIC INFLAMMATION IS ASSOCIATED WITH LOW ULTRASOUND VELOCITY IN OLDER MEN, A POPULATION BASED STUDY (LASA)

D. den Uyl - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Systemic inflammation

Interleukin

METFORMIN: A VALID ADD-ON DRUG IN THE TREATMENT OF PSORIATIC ARTHRITIS - RANDOMIZED CONTROLLED TRIAL

A. Abou-Raya - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Systemic inflammation

ILS-969

SERUM APOLIPOPROTEIN B IS ASSOCIATED WITH INCREASED RISK OF THE PRESENCE AND PROGRESSION OF CAROTID ATHEROSCLEROSIS IN PATIENTS WITH PSORIATIC ARTHRITIS

L. S. Tam - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Interleukin

SECUKINUMAB REDUCES HSCRP LEVELS IN SUBJECTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND CONCOMITANT PSORIATIC ARTHRITIS: A SUB-ANALYSIS FROM THE PHASE 3 ERASURE STUDY

A. Gottlieb - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

secukinumab

THERE IS NO RELATIONSHIP BETWEEN GLUCAGON LIKE PEPTIDE-1 AND INFLAMMATION IN PSORIASIS AND PSORIATIC ARTHRITIS

M. Keser - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Glucocorticoid

Filters

1408 Abstracts